Search
Showing results for "clinical trials"
CDKL5 deficiency disorder (CDD) is a rare developmental and epileptic encephalopathy. Ganaxolone, a neuroactive steroid, reduces the frequency of major motor seizures in children with CDD. This analysis explored the effect of ganaxolone on non-seizure outcomes.
The EQ-5D-5L is a generic health utility instrument for measuring health-related quality of life (HRQoL), with self-report and proxy report versions for children (EQ-5D-Y-5L). Children with intellectual disability (ID) are a heterogeneous population whose impairments and comorbidities place them at risk of poor HRQoL. This study aimed to describe the content validity and suitability for children with ID of a proxy report version of the EQ-5D-Y-5L as seen by their caregivers.
This study used qualitative methods to explore how adolescents with Duchenne muscular dystrophy used a powered wheelchair standing device in their daily lives
Our findings contribute to the genotype–phenotype data for atypical nested 22q11.2 duplications, with implications for genetic counseling
Mothers of children with autism without ID had increased risk of cancer, which may relate to common genetic pathways
Australia’s TGA has granted a provisional determination to Pfizer, allowing the pharmaceutical company to apply for approval to extend its COVID-19 vaccine to children aged 6 mths - 4 yrs.
A ground-breaking global clinical trial to improve the lifelong lung health of children born extremely prematurely has been awarded a Medical Research Future Fund (MRFF) International Clinical Trials Collaborations Grant totalling almost $3 million.
Dr Nick Gottardo, Co-Head of The Kids Research Institute Australia's Brain Tumour Research Team, has been announced a nominee for the 2018 WA Australian of the Year Award
The Early Moves study is investigating whether a baby’s early movements can predict difficulties with learning (known as cognitive impairment) later in childhood.
Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group